Synaptogenix Abstract Highlighting Bryostatin-1 Benefits In Severe Alzheimer's Disease Accepted For Presentation At 11th International Brain Research Organization World Congress Of Neuroscience
Portfolio Pulse from Happy Mohamed
Synaptogenix, Inc. (NASDAQ:SNPX) announced that an abstract featuring secondary endpoint data of its Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th International Brain Research Organization World Congress of Neuroscience. The trial data showed that Bryostatin-1 can prevent cognitive decline in advanced Alzheimer's disease patients. The company is also exploring strategic non-dilutive investment partners to facilitate continuing Bryostatin-1 development.
July 13, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Synaptogenix's Phase 2 trial data on Bryostatin-1 shows potential in preventing cognitive decline in advanced Alzheimer's disease patients. This could positively impact the company's stock as it indicates progress in their research and development efforts.
The acceptance of Synaptogenix's abstract for presentation at a prestigious neuroscience congress indicates recognition of their work in the scientific community. The positive trial data on Bryostatin-1 shows potential for the drug in treating advanced Alzheimer's disease, which could lead to increased investor interest and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100